Twenty different EV serotypes were detected; E9, E6 and CAV9 being found most frequently, whereas all but one HPeVs were type 3. Over this period, HPeV3 was identified as the most prevalent picornavirus type in CNS-related infections with similarly high incidences of EV infection frequencies in very young children. The highly sensitive virus typing methods applied in this study will assist further EV and HPeV screening of sepsis and meningitis cases as well as in future molecular epidemiological studies and population surveillance.
were obtained from young infants (<3 months). HPeV infections were seen exclusively in children under the age of three months (31/1105; 2.8%), and confined to spring on even-numbered years (22% in March 2006, 25% in April 2008 and 22% in March 2010). In contrast, EV infections were distributed widely across the years.
Twenty different EV serotypes were detected; E9, E6 and CAV9 being found most frequently, whereas all but one HPeVs were type 3. Over this period, HPeV3 was identified as the most prevalent picornavirus type in CNS-related infections with similarly high incidences of EV infection frequencies in very young children. The HEV-A to D (Hyypia et al., 1997 , Stanway et al., 2005 , with species B variants (including echoviruses, CBVs and CAV9) being the viral cause of CNS-associated infections in Europe identified most frequently.
Along with this reorganisation of enteroviruses was the recognition that two echoviruses, E22 and E23, were different genetically and biologically from other members in the Enterovirus genus. These two serologically distinct viruses were originally isolated and characterised over 50 years ago during a summer diarrhoea outbreak in America (Wigand & Sabin, 1961) . However, they were recognised as genetically distinct from enteroviruses in the early 1990s (Hyypia et al., 1992) and subsequently reassigned to a new picornavirus genus, Parechovirus (King et al., 1999) as human parechovirus (HPeV) types 1 and 2. Since then, a further twelve types (HPeV3 to 14) known to infect human have been discovered (Harvala et al., 2010) . 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w Although HPeV infections are common and the clinical course is usually mild, they have been recently associated with sepsis-like disease in very young children (Boivin et al., 2005 , Harvala et al., 2009 , Wolthers et al., 2008 ).
There is a high incidence of EV and HPeV infections in early childhood, as indicated by the high seroprevalence by the time children reach school age (JokiKorpela & Hyypia, 2001 , Tauriainen et al., 2007 . Although these infections are mostly asymptomatic, newborn infants are considered to be at a higher risk of severe EV (and HPeV) infection because of the immaturity of their immune system. Previous reports suggest that the risk of symptomatic neonatal EV and HPeV disease varies by infecting type, and that CBVs, E11 and HPeV3 are most commonly associated with severe neonatal sepsis-like illness (Harvala et al., 2009 , Khetsuriani et al., 2006a , Khetsuriani et al., 2006b ). However, fever in young infants can be bacterial in origin and thus it often necessitates a complete set of investigations including blood and urine culture, lumbar puncture as well as the initiation of broad-spectrum antibiotic therapy. This may be avoided in many cases if a rapid diagnosis of EV and HPeV infections could be made.
Traditionally, the diagnosis of EV or HPeV infections had relied on obtaining a positive viral culture from stool, nasopharyngeal swab or cerebrospinal fluid (CSF) samples. This often slow, laborious and insensitive virus detection method has been largely replaced by nucleic acid amplification methods such as reverse-transcriptase polymerase chain reaction (RT-PCR) for detection of viral RNA (Arola et al., 1996 , Chapman et al., 1990 , Hyypia et al., 1989 , Olive et al., 1990 , Zoll et al., 1992 .
Typically, RT-PCR assays target the 5'untranslated region, highly conserved between all four EV species, and between all known types of HPeV. Although extremely useful for virus screening, amplicon sequences from the 5'NCR provide little or no Amplification of VP1 sequences. Sufficient volumes of CSF were available for typing from 159 of the 201 EV-positive samples. Extracted RNA was amplified by a combined RT and first round PCR using the Superscript III (Invitrogen) followed by a second amplification reaction with nested primers specific for species A and B VP1 sequences as previously described . Positive HPeV samples were amplified in the VP3/VP1 junction region and sequenced between nucleotide positions 2182 and 2437 to identify HPeV types as described previously (Harvala et al., 2008) .
Nucleotide sequencing and serotype identification. Amplified DNA was directly sequenced using the BigDye Terminator kit (Applied Biosystems, Warrington, UK).
Sequences were edited and aligned using the Simmonics sequence editor (http://www.virus-evolution.org). Sequences have been assigned GenBank accession numbers xxxxx-yyyyy. Epidemiological and clinical associations of HPeV and EV infections. All children infected with HPeV were young infants (< 3 months of age, Fig. 2 ) with an average detection frequency in this subject group of 2.8% (31 of 1105). In contrast, EV infections were widely distributed among most age groups, with the highest frequency seen in young adults aged between 21 and 36 years (43/510; 8.6%). However, a 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Fig. 2) . The highest frequency of HSV1 and VZV infections was found in study subjects over 65 years of age, whereas HSV2 and Mumps virus infections occurred predominantly in the younger adults group (21-36 years and 37-65 years; data not shown). There was no significant over-representation of males among those infected with EV (103 male, 97 female) or HPeV (16 male, 15 female).
Adults infected with EV presented almost exclusively with suspected viral meningitis, whereas young children with HPeV and EV infections were referred with fever and sepsis-like illness (Table S1 ; Supplementary Material). Overall, HPeV presented with greater disease severity; four of 31 (13%) HPeV-positive subjects were treated on the High-Dependency / Intensive Care Units at time sampling compared to 5 from 198 (2.5%) infected with EV (p = 0.023; Fisher's Exact Test).
EV and HPeV infections in young infants. The remarkable high incidence of HPeV infections in children under the age of three months were largely confined to spring time on even years (22% in March 2006 , 25% in April 2008 and 22% in March 2010 Fig. 3), whereas EV infections were absent in this age group during these months. The prevalence of EV infections (11.8%) in young infants (<3 months) generally exceeded that of HPeV infections (4.1%). Interestingly, the frequency of EV infections was 12.0% (88/748) in children under the age of 3 months referred from home, while only 6 EV infections were diagnosed in 586 (1%) neonates remaining in hospital after birth in RIE Neonatal Unit (NNU) (p <0.001; Fig. 4) . A similar discordance in HPeV incidence was observed between these two groups with a 4% detection frequency EV and HPeV type identification. To identify infecting EV serotypes, amplification of VP1 gene was performed. Regions amplified in VP1 allowed previously assigned EV serotypes to be reliably identified ). An extremely high proportion of (uncultured) CSF samples could be directly typed for EVs ( Similarly to HPeV3 infections (30/30), all E16 infections (5 patients) as well as most E25 (6/7; 86%) and E11 (5/7; 71%) infections were seen in young infants (<3 months of age). Most very young children infected with EV or HPeV presented with sepsislike disease, whereas older children and adults commonly had meningitis (Table S1; Supplementary data). All EV infections were reported to the Health Protection Agency, England. Furthermore, HSV2, VZV and mumps virus were associated with meningitis and HSV1 with encephalitis (data not shown). Enterovirus diversity. Over the 5-year study period, the most common enterovirus serotypes identified in Edinburgh were E9, E6, CAV9, E30 and E18. Three of these (E9, E30 and CAV9) were also among the most abundant serotypes isolated from clinical specimens in the UK previously in 1975 to 1994 (Maguire et al., 1999) . E6, E9 and E30 were also among the most frequently reported serotypes in the United States in 1970 to 2005 (Khetsuriani et al., 2006a) , and similarly E30 and E6 in continental Europe in 2000s (Antona et al., 2007 , Blomqvist et al., 2008 . In contrast to most previous surveillance data based on virus isolation outside South-East Asia, a total of four different species A enterovirus serotypes were detected (CAV2, CAV6, CAV16 and EV71) in association with neonatal sepsis. This higher frequency of species A variants is consistent with a previous study of viraemia frequency in Scottish blood donors, where CAV16 and EV71 were amongst the identified EV types 
Detection of HPeV3.
In contrast to the diversity of enteroviruses detected in CSF, all but one of the 31 parechovirus-positive samples identified were type 3. Over the 5-year study period, it was the most prevalent picornavirus type in CNS-related infection. Comparison of genetic variants in the current study with those detected in previous surveillance provides evidence for a major change in parechovirus molecular epidemiology; HPeV1 (named as E22 at that time and thus part of enterovirus surveillance) was the second most prevalent serotype in the UK detected by virus isolation between 1975 and 1994 (Maguire et al., 1999) . Similarly, HPeV1 was (Hovi et al., 1996 , Khetsuriani et al., 2006a . Although it could be argued that the lack of HPeV3 detection in these earlier surveys directly resulted from putative insensitivity of virus isolation for this virus type (Benschop et al., 2010) , it is nevertheless clear that a major change in either the community circulation of HPeV1 or its disease outcomes has occurred over the last 3 decades.
HPeV3 infections differed considerably in their seasonality from enteroviruses, being detected exclusively in CSF samples collected in Edinburgh in 2006, 2008 and 2010 (Fig. 3) . This biennial cycle is consistent with previous reports of much higher frequencies of HPeV3 infections in even-numbered years between 2000 and 2006 , and the virtual absence in intervening years (Benschop et al., 2008 , van der Sanden et al., 2008 . To an extent, this periodicity resembles the regular increases in reported cases of several of the commonly circulating EV serotypes. For example, E30 shows a 4-5 year periodicity based on both USA and European surveillance data (Antona et al., 2007 , Khetsuriani et al., 2006a , Trallero et al., 2010 , while E9 shows a 2-3 year cycle. The re-appearance of E30 and E9 variants after an eclipse phase is associated with the emergence of novel recombinant genetic lineages of the viruses (McWilliam Leitch et al., 2009 , McWilliam Leitch et al., 2010 . This is however not the case in HPeV3; the variants circulating in 2006 and 2008 were almost identical in the VP3/VP1 region and sequence analysis of the 3Dpol region did not provide any evidence of the emergence of novel recombinant forms over the ellipse period (Calvert et al., 2010) . The phenomena underlying the biennial cycle of HPeV3 infections and its much greater frequency in spring thus remains to be determined. proportion of all EV infections (47%) were observed in infants younger than three months of age. This is higher than reported previously; enterovirus infection in the neonatal period accounted for about 10% of the total number of reported cases of enterovirus infections in the United States, whereas children <1 year of age accounted for 44% of reports (Khetsuriani et al., 2006a) . National surveillance data from France and the UK has shown that the vast majority of EV infections occur in young children, with infants below the age of one year accounting for about a third of all cases (Antona et al., 2007 , Maguire et al., 1999 .
As found in the current study, it has also been shown that the relative frequency and predominant serotypes of enteroviruses affecting neonates differ from the pattern observed in the general population. Indeed, the remarkable variability in the proportion of young infants infected with enteroviruses could be partly accounted by seasonal changes in the circulation of serotypes associated with CNS-related disease in young infants. These include CBVs, E11, E16 and E25, each of which typically target neonates (Verboon-Maciolek et al., 2003) , and E9 and E30 which infect neonates much less frequently than older persons (Khetsuriani et al., 2006a , Khetsuriani et al., 2006b ). In this study, the lowest proportions of EV infections in young infants (<3 months of age; 36%) were observed in 2007, the year when E9 and E30 were the two viruses detected most frequently, accounting for 57% of all EV infections. Conversely, the highest proportion of young infants (<3 months of age) infected with EV (57%) occurred in 2009, when CBVs, and E11 were amongst the two most prevalent viruses. Furthermore, E16 was positively associated with infections in very young children (<3 months; all infections in this age group). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w Although marked differences in the age distribution of different EV serotypes were observed, an even more polarised age distribution was observed in HPeV infections. These were detected exclusively in CSF samples obtained from young infants (<3 months), and entirely absent from older children and adults. These findings are consistent with the previous analysis of HPeV infection (Harvala et al., 2009 ); the parallel observation that HPeV3 detection in respiratory samples was similarly age-restricted providing evidence that the virus circulation is limited to children in this very young age group. This association is therefore not the result of biased sampling and greater likelihood of sampling because of disease severity, or a clinical need to identify viral from bacterial causes of sepsis.
The observation that both EV or HPeV infections were restricted almost entirely to infants who had been admitted to hospital from home (Fig. 4) and were almost entirely absent from children in the same age range who had remained hospitalised after birth, provides clear evidence for community sources of infection that are largely curtailed in a hospital setting. These observations reassure that nosocomial transmission of EVs and HPeV in the Edinburgh neonatal unit was extremely uncommon over the five-year study period. The findings also indicate how diagnostic screening for EVs and HPeV may be targeted more effectively as there would be a case to exclude those who have remained in hospital after birth from testing.
Why has the incidence of neonatal EV and HPeV infections increased?
One of the major findings in the current study was the remarkable frequency of EV and HPeV infections in children less than three months old, presenting with sepsis-like illnesses.
The observed frequencies are much higher than reported previously in this age range (Figueroa et al., 1989 , Khetsuriani et al., 2006a , Legay et al., 2002a , and cannot be entirely attributed to improvement in the effectiveness of screening methodologies (although the greater ability of PCR to detect HPeV3 and species A EVs compared to virus culture undoubtedly contributed partly to the increased detection frequency in CSF).
In seeking to explain this change, it might be proposed that HPeV3 and several of EVs specifically found in neonates may have changed in their biological properties (associated with a greater propensity to infect systemically), in their epidemiology and transmission, or that there have been systematic changes in host susceptibility over the past decades. One factor supporting the latter hypothesis is the evidence for a progressive lowering of maternal seroprevalence and lack of passively transferred protective neutralizing antibodies transferred passively in an increasing proportion of neonate and infants. The changing epidemiology of enterovirus infections has indeed been demonstrated clearly in Finland (Viskari et al., 2000) : the proportion of pregnant women lacking antibodies to CBV4 increased from 6% in 1983 to 17% in 1995 (p<0.001). Increasing number of young infants will therefore lack the protective maternal antibodies to viruses circulating in the community, and increase the likelihood of developing severe CNS-associated (sepsis-like) EV disease.
Whether such changes in the viral circulation account for the increasing incidence of HPeV3-associated sepsis-like illness in neonates is unclear, as are the underlying reasons for the major clinical and epidemiological differences from HPeV1, which is well documented to cause asymptomatic or mild infections and shows a strikingly high incidence in the first two years of life (Joki-Korpela & Hyypia, 1998 , Tapia et al., 2008 , Tauriainen et al., 2007 . The close to universal adult seropositivity for HPeV1 contrasts with that of HPeV3; over 30% of child-bearing F o r P e e r R e v i e w aged women has been shown to lack antibodies to HPeV3 (Ito et al., 2004) . However, unlike the situation with EVs, the lower adult seroprevalence of HPeV3 may have resulted directly from its relatively recent emergence compared to other HPeV types.
Through analysis of the genetic diversity of circulating currently and historical isolates of HPeV3, it has been estimated that a common ancestor for this type appeared in the human population as recently as 1987 (Calvert et al., 2010) , approximately 10 years before it was first isolated in Japan and Canada (Abed & Boivin, 2005 , Ito et al., 2004 . HPeV3 may therefore have not spread sufficiently far into adult human populations to provide the essential levels of maternal protection required to prevent neonatal disease.
This proposed scenario contrasts with HPeV1, where close to universal maternal seropositivity may account for the current almost complete lack of neonatal disease associated with this type. Sewage surveillance in Edinburgh indeed documents the predominance of HPeV1 over other HPeV types circulating in the local community (Calvert et al., unpublished observations) . Interestingly, diagnosed HPeV1 infections were substantially more frequent and more severe in the 1980s (Figueroa et al., 1989 , Koskiniemi et al., 1989 , Legay et al., 2002b , where it accounted for close to 8% of all HPeV/EV infections in national surveillance systems (Antona et al., 2007 , Khetsuriani et al., 2006a , Khetsuriani et al., 2006b , Maguire et al., 1999 . We might speculate that the emergence of HPeV1 simply preceded that of HPeV3 and these disease presentations originated similarly from a lack of universal maternal exposure at that time.
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